This article originally published by PharmaTimes Online The National Institute for Heath and Care Excellence (NICE) has turned down NHS funding of Celgene’s Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults. There is currently no maintenance treatment for newly diagnosed multiple myeloma in people who...Continue Reading